Japanese guidelines for adult asthma 2017☆


Adult bronchial asthma is characterized by chronic airway inflammation, and presents clinically with variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma induces airway remodeling, leading to intractable asthma. The number of patients with asthma has increased; however, the number of patients who die of asthma has decreased (1.2 per 100,000 patients in 2015). The goal of asthma treatment is to enable patients with asthma to attain normal pulmonary function and lead a normal life, without any symptoms. A good relationship between physicians and patients is indispensable for appropriate treatment. Long-term management by therapeutic agents and elimination of the causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy differentiate between mild and intensive treatments; each step includes an appropriate daily dose of an inhaled corticosteroid, varying from low to high levels. Long-acting β2-agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonist are recommended as add-on drugs, while anti-immunoglobulin E antibody and oral steroids are considered for the most severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled β2-agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by choosing treatment steps for asthma in accordance with the severity of exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-induced asthma, and pregnancy are also important issues that need to be considered in asthma therapy.

Full Text


(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: United Action for Allergy and Asthma https://t.co/Bssbmnu3cF, see more https://t.co/CpGiFuOOYd
Interasma RT @Aller_MD: Top story: United Action for Allergy and Asthma https://t.co/xdIbmmWD5j, see more https://t.co/jgCeENQuZt
Interasma RT @ARIAGuideline: Emerging technologies for predictive medicine in chronic airway diseases... https://t.co/1uOqcIwQ1o
Interasma RT @Aller_MD: “Global Market Study on AR: Immunotherapy Segment Projected to be the Fastest Growing Segment” https://t.co/FC1n10wV6o https:…
Interasma RT @Aller_MD: Top story: The Myth of Drug Expiration Dates - ProPublica https://t.co/8bS0FafKTF, see more https://t.co/jgCeENQuZt

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA